Merck signs up to $3.3 billion cancer drug deal with China-based LaNova | Reuters
Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months after a similar therapy from …Read More
The Heartbeat of World events
Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months after a similar therapy from …Read More
